the opioid crisis; (2) Perspectives on, and experiences with, syringe services program (SSP); (3) Continued discussion on HIV transmission risk in the context of Antiretroviral Therapy (ART) use and Viral Suppression (Treatment as Prevention or TasP); (4) Anti-bullying policies in schools; and (5) Updates from Workgroups. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine Baker, 
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

FOR FURTHER INFORMATION CONTACT:

Elaine Baker, 
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Office of Infectious Diseases (BSC, OID)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, Office of Infectious Diseases (BSC, OID). This meeting is open to the public, limited only by the space available; the meeting room will accommodate up to 100 people. The public is also welcome to listen to the meeting by telephone, limited only by the number of ports available (50); the toll-free dial-in number is 1-888-998-7982, with a pass code of 1252535.

DATES: The meeting will be held on May 3, 2018, 8:30 a.m. to 12:00 p.m., EDT, and May 10, 2018, 8:30 a.m.–3:30 p.m., EDT.

ADDRESSES: CDC, Global Communications Center, Building 19, Auditorium B3, 1600 Clifton Road NE, Atlanta, Georgia 30329.

FOR FURTHER INFORMATION CONTACT:

Dometa Ouisley, Office of Science and Administration, Office of Public Health Preparedness and Response (OPHPR), concerning strategies and goals for the programs and research within OPHPR, monitoring the overall strategic direction and focus of the OPHPR Divisions and Offices, and administration and oversight of peer review for OPHPR scientific programs. For additional information about the Board, please visit: http://www.cdc.gov/phpr/science/counselors.htm.

Matters To Be Considered: The agenda will include discussions on Day one of
the meeting that will cover briefings and BSC deliberation on the following topics: Interval updates from the OPHPR Director and OPHPR Divisions and Offices; updates from the Biological Agent Containment working group; discussion of Industry, Private Sector, and Public Health Interactions Supporting Emergency Preparedness and Response; and Preparedness Updates from Liaison Representatives.

Day two of the meeting will cover briefings and BSC deliberation on the following topics: OPHPR Office of Policy, Planning and Evaluation activities; CDC’s Data Preparedness activities; Public Health System Perspectives on Hurricanes Response; and Excellence in Response Operations Initiative. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

When commenting, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in any one of the following ways:

1. Electronically. You may send your comments electronically to http://www.regulations.gov. Follow the instructions for “Comment or Submission” or “More Search Options” to find the information collection document(s) that are accepting comments.

2. By regular mail. You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs Division of Regulations Development Attention: Document Identifier/OMB Control Number Room C4—26—05 7500 Security Boulevard Baltimore, Maryland 21244—1850.

To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, you may make your request using one of following:

2. Email your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov.
3. Call the Reports Clearance Office at (410) 786—1326.

FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786—4669.

SUPPLEMENTARY INFORMATION:

Contents

This notice sets out a summary of the use and burden associated with the following information collections. More detailed information can be found in each collection’s supporting statement and associated materials (see ADDRESSES).

CMS-10191  Medicare Parts C and D Program Audit and Timeliness Monitoring Data Requests

Under the PRA (44 U.S.C. 3501—3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term “collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA requires federal agencies to publish a 60-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice.

Information Collection

1. Type of Information Collection Request: Revision of a currently approved collection; Title of Information Collection: Medicare Parts C and D Program Audit and Timeliness Monitoring Data Requests; Use: Medicare Part D plan sponsors and Medicare Advantage organizations (collectively referred to as sponsoring organizations) are required to comply with all Medicare Parts C and D program requirements. In 2010, the explosive growth of these sponsoring organizations precipitated the need for CMS to develop an annual audit strategy to ensure that we evaluate sponsoring organizations compliance with the program requirements. In addition to describing how sponsoring organizations are selected for audit and which program areas will be audited, CMS’ annual audit strategy reflected a move to a more targeted, data-driven, and risk-based audit approach. Since 2010, CMS has continued to focus on assisting the industry with improving their operations to ensure beneficiaries receive appropriate access to care. CMS has developed audit protocols that focus on high-risk areas that have the greatest potential for beneficiary harm.

CMS’ program audit protocols are posted to the CMS website each year for use by sponsoring organizations to prepare for their audit. Currently CMS utilizes the following 5 protocols to audit sponsoring organizations’ performance: Compliance Program Effectiveness (CPE), Formulary Administration (FA); Coverage Determinations, Appeals, and Grievances (CDAG); Organization Determinations, Appeals, and Grievances (ODAG), Special Needs Program Model of Care (SNP–MOC) (only administered on organizations who operate SNPs). Beginning in audit